Overview

A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease

Status:
Recruiting
Trial end date:
2024-06-13
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety, tolerability and effect of study drug LY3372689 in participants with early symptomatic Alzheimer's Disease
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company